Drug Trial Radar · NCT03267433
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
689
Planned (sponsor's estimate)
Start
Nov 27, 2017
Primary completion
Jan 31, 2027
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Immunotherapy with rituximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.
Conditions
- Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell TransplantationProcedure
Undergo HCT
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirateProcedure
Undergo bone marrow biopsy and aspirate
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy and aspirate
Computed TomographyProcedure
Undergo CT or PET/CT
Positron Emission TomographyProcedure
Undergo PET or PET/CT
RituximabBiological
Given IV
Rituximab and Hyaluronidase HumanBiological
Given SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS) in mantle cell lymphoma (MCL) patients in minimal residual disease (MRD)-negative complete remission (CR) who undergo auto-hematopoietic stem cell transplant (HCT) followed by rituximab versus (vs.) maintenance rituximab aloneTime frame: Time between randomization and death from any cause, assessed up to 10 years
Locations
375 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Kingman Regional Medical Center
Kingman, Arizona
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
PCR Oncology
Arroyo Grande, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
City of Hope Comprehensive Cancer Center
Duarte, California
UC San Diego Moores Cancer Center
La Jolla, California
Contra Costa Regional Medical Center
Martinez, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
UC San Diego Medical Center - Hillcrest
San Diego, California
UCSF Medical Center-Parnassus
San Francisco, California
BASS Medical Group - Lennon
Walnut Creek, California
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado
The Medical Center of Aurora
Aurora, Colorado
Boulder Community Hospital
Boulder, Colorado
Boulder Community Foothills Hospital
Boulder, Colorado
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado
Rocky Mountain Cancer Centers - Centennial
Centennial, Colorado
Cancer Center of Colorado at Sloan's Lake
Denver, Colorado
Denver Health Medical Center
Denver, Colorado
National Jewish Health-Main Campus
Denver, Colorado
The Women's Imaging Center
Denver, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado
SCL Health Saint Joseph Hospital
Denver, Colorado
Rocky Mountain Cancer Centers-Rose
Denver, Colorado
Rose Medical Center
Denver, Colorado
Mountain Blue Cancer Care Center - Swedish
Englewood, Colorado
Showing 40 of 375 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.